Laddar...
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope(®) (biosimilar rhGH) was approved by the European Medicines Agency in 2006, with approval granted...
Sparad:
| I publikationen: | Drug Des Devel Ther |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5439985/ https://ncbi.nlm.nih.gov/pubmed/28553080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S130909 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|